Multicenter Evaluation of a Novel, Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues

The mutated BRAF oncogene represents a therapeutic target in malignant melanoma. Because BRAF mutations are also involved in the pathogenesis of other human malignancies, the use of specific BRAF inhibitors might also be extended to other diseases in the future. A prerequisite for the clinical application of BRAF inhibitors is the reliable detection of activating BRAF mutations in routine histopathological samples. In a multicenter approach, we evaluated a novel and fully automated PCR-based system (Idylla) capable of detecting BRAF V600 mutations in formalin-fixed, paraffin-embedded tissue within 90 minutes with high sensitivity.

Source: Journal of Molecular Diagnostics - February 24, 2016 Category: Pathology Authors: Ana-Iris Schiefer, Laura Parlow, Lisa Gabler, Ildiko Mesteri, Oskar Koperek, Andreas von Deimling, Berthold Streubel, Matthias Preusser, Annika Lehmann, Udo Kellner, Patrick Pauwels, Suzan Lambin, Manfred Dietel, Michael Hummel, Frederick Klauschen, Peter Tags: Regular Article Source Type: research